Company Snapshot
- Ticker
- CRL
- Name
- CRL
- Sector
- None
- Currency
- 0
- Relative Volume
- None
- Market Cap
- 9589153050.000000
- Volume
- 1,107,338
- Avg Volume (3M)
- 999,344
CRL
CRL
Last update recent
194.85
+8.86
(+4.76%)
Market Cap
9589153050.000000
Dividend Yield
0.00%
1Y Return
None%
Beta
None
Price & Moving Averages
Interactive chart with SMA overlays and intraday breadth.
Profitability
- Revenue
- 4023704000.000000
- EPS
- -1.55
- Dividend / Share
- None
- Total Dividends
- $0.00
- Dividend Yield
- 0.0%
- Net Income
- -83482000.000000
- Net Margin
- -2.07%
- Payout Ratio
- 0.0%
- Qtly Growth YoY
- None
Valuation & Quality
- P/E
- -114.86
- Forward P/E
- None
- P/S
- 2.38
- P/B
- 2.78
- Beta
- None
- Debt / Equity
- 0.76
- Current Ratio
- 1.37
- Return on Equity
- -0.02%
- Return on Assets
- -0.01%
Technicals & Returns
- Distance vs 200 DMA
- 24.69%
- 200 DMA
- 156.27
- Distance vs 50 DMA
- 10.41%
- 50 DMA
- 176.48
- Return 1Y
- None%
- Return YTD
- None%
- Beta (Trailing)
- None
- Relative Volume
- None
Factor Lens
Plot valuation, momentum, or volume trends.
Seasonal Performance
Company Overview
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in s Read more
- Name
- CRL
- Industry
- Medical - Diagnostics & Research
- CEO
- Mr. James C. Foster J.D.
- Employees
- 20,400
- IPO Date
- 2000-06-23
- Phone
- 781 222 6000
- Address
- None
- Website
- https://www.criver.com
Dividend Yield
0.00%
TTM Distributions
$0.00
Latest News
Curated headlines from premium sources.
21% TLX PLUNGE: Hagens Berman Urges Telix Investors to Act by Jan. 9 in Class Action Suit Over SEC Subpoena & FDA CRL on Manufacturing Failures
Partner Reed Kathrein Scrutinizing Alleged Misstatements on Prostate Cancer Drug TLX591 Progress and Third-Party Manufacturing Deficiencies (Form 483) SAN FRAN…
21% TLX PLUNGE: Hagens Berman Urges Telix Investors to Act by Jan. 9 in Class Action Suit Over SEC Subpoena & FDA CRL on Manufacturing Failures
Partner Reed Kathrein Scrutinizing Alleged Misstatements on Prostate Cancer Drug TLX591 Progress and Third-Party Manufacturing Deficiencies (Form 483) Partner …
Charles River Extends Commitment to Advanced Therapy Developers with Second Incubator Program Cohort
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the second cohort of its Cell & G…
Federated Hermes Inc. Raises Stock Holdings in Charles River Laboratories International, Inc. $CRL
Federated Hermes Inc. lifted its stake in shares of Charles River Laboratories International, Inc. (NYSE: CRL) by 55,929.3% during the second quarter, accordin…
Telix (TLX) Facing Securities Class Action Lawsuit Over Alleged Dual Regulatory Failures: SEC Subpoena & FDA CRL on CMC/Supply Chain – Hagens Berman
Partner Reed Kathrein Scrutinizes Alleged Misstatements on Prostate Cancer Drug TLX591 Progress and Third-Party Manufacturing Deficiencies (Form 483) Partner R…
Edgestream Partners L.P. Invests $1.80 Million in Charles River Laboratories International, Inc. $CRL
Edgestream Partners L.P. purchased a new stake in Charles River Laboratories International, Inc. (NYSE: CRL) in the second quarter, according to its most recen…